Patents by Inventor Giuseppe Pippia

Giuseppe Pippia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Liquid formulation
    Patent number: 11357855
    Abstract: The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: June 14, 2022
    Assignee: LUODA PHARMA LIMITED
    Inventors: Nicholas Bova, Stephen Page, Giuseppe Pippia
  • LIQUID FORMULATION
    Publication number: 20190381175
    Abstract: The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 19, 2019
    Inventors: Nicholas Bova, Stephen Page, Giuseppe Pippia
  • Liquid formulation
    Patent number: 10413610
    Abstract: The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: September 17, 2019
    Assignee: LUODA PHARMA LIMITED
    Inventors: Nicholas Bova, Stephen Page, Giuseppe Pippia
  • Liquid Formulation
    Publication number: 20180028665
    Abstract: The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 1, 2018
    Applicant: Luoda Pharma Pty Ltd
    Inventors: Nicholas Bova, Stephen Page, Giuseppe Pippia
  • Liquid formulation
    Patent number: 9808529
    Abstract: The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: November 7, 2017
    Assignee: Luoda Pharma Pty Ltd
    Inventors: Nicholas Bova, Stephen Page, Giuseppe Pippia
  • LIQUID FORMULATION
    Publication number: 20150148335
    Abstract: The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 28, 2015
    Inventors: Nicholas Bova, Stephen Page, Giuseppe Pippia
  • TREATMENT OF NEONATE FOALS WITH MELOXICAM
    Publication number: 20110212948
    Abstract: A method of administering meloxicam containing compositions to neonate foals of 6 weeks of age or less is provided. The inventors have discovered that foals of 6 weeks of age or less can have meloxicam administered at a dosage of 0.6 mg/kg without any negative or adverse reaction by the foal. The method also provides a dosing regimen for obtaining first peak plasma concentrations of approximately 800 ng/ml, average plasma concentration levels of 200 ng/ml for 6 hours after a single dose, and sustained plasma concentration levels of 100 ng/ml with twice daily dosing.
    Type: Application
    Filed: July 10, 2009
    Publication date: September 1, 2011
    Inventors: Giuseppe Pippia, Sharanne Raidal